Finally, there seemed more metastatic carcinomas carried BRCA2 mutation as compared to the primary tumors, which suggests an increasing role of PARP inhibitors in the treatment of metastatic pancreatic cancer [27,36,37]. The gene discussed is BRCA2; the disease is metastatic carcinoma.